These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration. Jeganathan VS; Verma N Curr Opin Ophthalmol; 2009 May; 20(3):223-5. PubMed ID: 19367163 [TBL] [Abstract][Full Text] [Related]
5. Pegaptanib for neovascular age-related macular degeneration. Maberley D Issues Emerg Health Technol; 2005 Dec; (76):1-4. PubMed ID: 16544440 [TBL] [Abstract][Full Text] [Related]
6. Quantitative comparison of optical coherence tomography after pegaptanib or bevacizumab in neovascular age-related macular degeneration. Joeres S; Kaplowitz K; Brubaker JW; Updike PG; Collins AT; Walsh AC; Romano PW; Sadda SR Ophthalmology; 2008 Feb; 115(2):347-354.e2. PubMed ID: 17628685 [TBL] [Abstract][Full Text] [Related]
7. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology. Ip MS; Scott IU; Brown GC; Brown MM; Ho AC; Huang SS; Recchia FM; Ophthalmology; 2008 Oct; 115(10):1837-46. PubMed ID: 18929163 [TBL] [Abstract][Full Text] [Related]
8. [VEGF inhibitors in ophthalmology]. Thys J; Dupont G; Rakic JM Rev Med Liege; 2009; 64(5-6):323-6. PubMed ID: 19642468 [TBL] [Abstract][Full Text] [Related]
9. Inhibitors of vascular endothelial growth factor (VEGF) in the management of neovascular age-related macular degeneration: a review of current practice. van Wijngaarden P; Qureshi SH Clin Exp Optom; 2008 Sep; 91(5):427-37. PubMed ID: 18637105 [TBL] [Abstract][Full Text] [Related]